MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple Turns 50: From Garage Startup to AI Crossroads 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
NEW YORK, Oct. 11, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Nevada on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) securities between December 16, 2015 and September 16, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/spectrum-pharmaceuticals-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the “FDA”) questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants’ public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/spectrum-pharmaceuticals-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
